Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial.


Journal

British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541

Informations de publication

Date de publication:
06 2020
Historique:
received: 05 09 2019
revised: 09 12 2019
accepted: 18 01 2020
pubmed: 5 4 2020
medline: 26 6 2020
entrez: 5 4 2020
Statut: ppublish

Résumé

This study assessed whether i.v. sildenafil citrate prevented acute kidney injury in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass. In a double-blind RCT, adults at increased risk of acute kidney injury undergoing cardiac surgery in a single UK tertiary centre were randomised to receive sildenafil citrate 12.5 mg kg The analysis population comprised eligible randomised patients that underwent valve surgery or combined coronary artery bypass graft and valve surgery, with cardiopulmonary bypass, between May 2015 and June 2018. There were 60 subjects in the sildenafil group and 69 in the placebo control group. The difference between groups in creatinine concentration was not statistically significant (MD: 0.88 μmol L These results do not support the use of i.v. sildenafil citrate for kidney protection in adult cardiac surgery. ISRCTN18386427.

Sections du résumé

BACKGROUND
This study assessed whether i.v. sildenafil citrate prevented acute kidney injury in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass.
METHODS
In a double-blind RCT, adults at increased risk of acute kidney injury undergoing cardiac surgery in a single UK tertiary centre were randomised to receive sildenafil citrate 12.5 mg kg
RESULTS
The analysis population comprised eligible randomised patients that underwent valve surgery or combined coronary artery bypass graft and valve surgery, with cardiopulmonary bypass, between May 2015 and June 2018. There were 60 subjects in the sildenafil group and 69 in the placebo control group. The difference between groups in creatinine concentration was not statistically significant (MD: 0.88 μmol L
CONCLUSIONS
These results do not support the use of i.v. sildenafil citrate for kidney protection in adult cardiac surgery.
CLINICAL TRIAL REGISTRATION
ISRCTN18386427.

Identifiants

pubmed: 32245569
pii: S0007-0912(20)30126-4
doi: 10.1016/j.bja.2020.01.030
pmc: PMC7271663
pii:
doi:

Substances chimiques

Phosphodiesterase 5 Inhibitors 0
Sildenafil Citrate BW9B0ZE037
Glucose IY9XDZ35W2

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

693-701

Subventions

Organisme : British Heart Foundation
ID : CH/12/1/29419
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/6/29947
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Am J Physiol Renal Physiol. 2011 Sep;301(3):F605-14
pubmed: 21653630
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1279-1287
pubmed: 29932345
Kidney Int. 2002 Mar;61(3):855-61
pubmed: 11849438
Cochrane Database Syst Rev. 2013 Sep 11;(9):CD003590
pubmed: 24027097
Indian J Pharmacol. 2014 May-Jun;46(3):281-5
pubmed: 24987174
N Engl J Med. 2015 Apr 9;372(15):1419-29
pubmed: 25853746
Am J Physiol Renal Physiol. 2009 Jan;296(1):F25-33
pubmed: 18971208
Circulation. 2009 Feb 3;119(4):495-502
pubmed: 19153273
Br J Clin Pharmacol. 2017 Apr;83(4):709-720
pubmed: 27779776
Heart Lung Circ. 2014 Jul;23(7):680-5
pubmed: 24613188
Open Heart. 2018 Oct 18;5(2):e000838
pubmed: 30364431
J Am Coll Cardiol. 2011 Aug 23;58(9):897-903
pubmed: 21851876
Ann Thorac Cardiovasc Surg. 2014;20(3):217-22
pubmed: 23574999
Crit Care. 2013 Oct 31;17(5):R262
pubmed: 24172587
Crit Care Med. 2011 Apr;39(4):793-802
pubmed: 21220998
Eur J Cardiothorac Surg. 2016 May;49(5):1403-10
pubmed: 26464453
Crit Care. 2014 Nov 20;18(6):606
pubmed: 25673427
Cardiovasc Res. 2018 May 1;114(6):822-829
pubmed: 29438488

Auteurs

Tracy Kumar (T)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Hardeep Aujla (H)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Marcin Woźniak (M)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Will Dott (W)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Nikol Sullo (N)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK; University of Nottingham, Royal Derby Hospital, Derby, UK.

Lathishia Joel-David (L)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Paolo Pais (P)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Dawn Smallwood (D)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK; School of Allied Health Sciences, De Montfort University, Leicester, UK.

Douglas Miller (D)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Bryony Eagle-Hemming (B)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.

Ana Suazo Di Paola (AS)

Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.

Shaun Barber (S)

Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.

Cassandra Brookes (C)

Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.

Nigel J Brunskill (NJ)

Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.

Gavin J Murphy (GJ)

Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK; Leicester Clinical Trials Unit, University of Leicester, Leicester, UK. Electronic address: gjm19@le.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH